Most drugs, with few notable exceptions, such as heparin, exert their effects not within the plasma compartment but in defined target tissues into which drugs must be distributed from the central compartment. Unfortunately, a complete and lasting equilibration between blood and tissue cannot always be taken for granted. This fact is also taken into account in local-regional strategies for drug applications, e.g., intra-arterial or intrathecal chemotherapy or intra-articular injections, which aim at delivering drugs to otherwise virtually inaccessible target sites.
Although it has been commonly believed that most antibiotics nearly achieve equilibrium in tissues and plasma (5, 6, 11) , recent studies have indicated that the antibiotic distribution process is characterized by high intertissue and intersubject variabilities ( Fig. 1 ) and that target site drug levels may substantially differ from corresponding plasma drug levels (15, 16, 22, 55, 57, 63, 65, 78, 80, 81, 83, 108, 109, 116, 188) . Suboptimal target site concentrations may have important clinical implications, as they may explain therapeutic failures (22, 80, 129) , in particular, for bacteria for which in vitro MICs are high (22, 80) ; in addition, it is conceivable that subinhibitory concentrations in tissues may also trigger bacterial resistance (76, 87, 117, 120) . Therefore, it is also recommended in standard reference texts on current medical treatment (78) that one consider impaired target site distribution, particularly when there are discrepancies between clinical response and susceptibility testing (78) . Data on tissue penetration of drugs therefore could provide important clinical information, especially since several studies have shown that the concentration profile at the target site is an important determinant of clinical outcome and is more predictive in this respect than the concentration in plasma (109, 129) .
Impaired tissue penetration of antibiotics is best recognized for central nervous system (CNS) infections (84, 121) . The barrier mechanism in the CNS and other organs, such as the eye, is the presence of active transport pumps that lead to target site concentrations which, even at equilibrium, are lower than those in plasma (5) . This mechanism, which has been well described both in vitro and in vivo, likely also is the reason for therapeutic failures in CNS and eye infections (5) .
However, besides CNS infections, many other situations in which impaired drug penetration and blood-tissue inequilibrium can be observed have been reported. In particular, antibiotic failures have been attributed to impaired target site penetration in cases of soft tissue infections (134) , osteomyelitis and orthopedic surgery (45, 98, 127) , peridontitis and odontogenic infections (1), endocarditis (94) , septic embolism (14, 142) , foreign body-and catheter-related infections (142), gastric ulcer (67) , hematomas (142) , epidermal infections (101), abscesses (142) , granuloma-inducing infections and tuberculosis (51, 186) , prostatitis (46) , eye infections (21) , ear infections (69) , tonsillitis (136) , sinusitis (50) , liver infections (139) , urinary tract infections (116, 142) , pelvic inflammatory disease (122) , solid malignancies (79, 129) , respiratory tract infections (126, 131) , heart-lung bypass surgery (22) , and septic shock (80) .
Studies on the distribution of active transporters and studies with P-glycoprotein knockout mice have indicated that active transporters may play a broader role in drug disposition, affecting tissue drug distribution in non-CNS organs substantially as well (143) . Nevertheless, in most of the above-mentioned situations, the barrier mechanism more likely is related to pH partitioning of acidic or alkaline drugs, which may occur in inflammatory lesions and in the prostate gland (5) . Another mechanism is the presence of functional or structural resistance of the capillary wall based on alterations in local blood flow, capillary density, capillary permeability, interstitial diffusion coefficients, and transcapillary oncotic and osmotic pressure gradients (36, 90, 102, 132) . In contrast to pH partitioning and active barrier mechanisms, mean tissue drug concentrations will eventually equal those in plasma if the capillary wall constitutes the sole, passive barrier to drug diffusion. However, since the rate of diffusion is low, this event could take a long time, and tissue drug concentrations will be subinhibitory, at least at the beginning of therapy.
FOUR COMMON MISCONCEPTIONS ABOUT TISSUE DRUG DISTRIBUTION
For many years, research on pharmacokinetics (PK) was limited for practical reasons to concentration measurements derived from matrices which were easy to obtain, such as blood and total tissue specimens. These approaches, however, caused considerable confusion, as their interpretation was flawed by four misconceptions.
(i) Indirect modeling of tissue drug levels from plasma drug concentration curves implied a seldom-communicated consensus on the fact that compartment models have no actual anatomical correlate and merely represent virtual values in hypothetical spaces. However, the body is a multimillion-compartment model, and studies of capillary physiology (36, 90, 102, 132) and PK have shown that rate constants for analyte transfer from plasma to tissues are heterogeneous and tissue specific (48, 113) (Fig. 1) . Although methods for the prediction of volume of distribution based on experimentally determined physicochemical parameters can predict the average volume of distribution at steady state within or very close to twofold the actual value (92) , it must be kept in mind that drug-based or plasma-based models refer to the process of penetration into hypothetical compartments as "tissue penetration." This concept is misleading, as it does not take into account the uniqueness of separate organ systems and disease processes. Thus, although plasma-based modeling may provide useful information in many cases, it must be kept in mind that it assumes rapid, unrestricted, and homogeneous diffusion processes in hypothetical spaces-assumptions that do not always hold true.
(ii) A second misconception was the reasoning that tissue is a uniform matrix. Although tissue antibiotic concentrations may be readily measured from total tissue biopsy specimens, total antibiotic concentration measurements from biopsy specimens may be misleading for several reasons. Most importantly, it must be considered that the actual target space for anti-infective agents, with few exceptions, such as infections with rickettsiae or chlamydiae, is the interstitial space fluid (ISF) (133) . If only overall tissue drug concentrations are measured, then the effective site concentrations of drugs that equilibrate exclusively with the extracellular space, such as ␤-lactams, may be underestimated (108) . This situation, in turn, will lead to an overestimation of the effective site concentrations of intracellularly accumulating drugs, such as quinolones or macrolides (108) . Thus, the admixture of various compartmental fluids will lead to a hybrid tissue drug concentration which is difficult to interpret.
A closely related misconception was the introduction of "tissue-partition coefficients" (3, 20, 125) . This concept, which is gleaned from the chemical concept of in vitro Nernst partition coefficients for drugs between a lipid phase and a water phase, assumes the presence of a tissue/blood partition coefficient under equilibrium conditions. For this purpose, the partitioning of a given compound between homogenized tissue and plasma is experimentally determined, and the value is used for further calculations. This concept, which was mainly used for physiologically based PK models (20) , however, is substantially flawed, as the basic assumption that tissue is a homogeneous phase comparable to a liquid phase is incorrect. Since the physiological structure of tissue compartments is destroyed during the procedure, the compound of interest interacts with various intracellular and extracellular components in an unphysiological way, and it becomes impossible to discriminate the in vivo ratio of the bound drug to the active drug.
Although approaches based on total tissue data are of limited value for the interpretation of drug efficacy, total tissue data may correlate with drug toxicity, e.g., nephrotoxicity of aminoglycosides.
(iii) A third misconception was the notion that the entire drug fraction present in various tissue spaces exerts pharmacologic activity. In fact, it has been shown that only the unbound drug fraction in the ISF has the ability to exert antiinfective efficacy, both in vitro and in vivo (31, 32, 33, 34, 86, 99, 184) . Clinical examples for the relevance of protein binding were given in an article by Wise (184) ; these included therapeutic failures with fusidic acid or ceftriaxone in gonorrhoea and the close relationship between the failure of cefoperazone in serious illness and the degree of protein binding. Besides the fact that only the free fraction exerts activity, it is also only the free fraction which has the ability to be distributed to the target site. This information was experimentally shown by various investigators, who found that differences in penetration were directly related to the free drug concentrations in serum (4, 13, 110) (Fig. 2) . Although this concept has been described best for antibacterial agents, it seems reasonable to assume that similar concepts hold true for liposomal and nonliposomal antifungal formulations.
It follows from these three considerations that an appropriate definition of tissue drug concentrations should imply in most cases the meaning of unbound interstitial drug concentrations and that a method which is to be considered the "gold standard" for the measurement of tissue drug concentrations should allow for the direct measurement of unbound antibiotic concentrations in the ISF of a given organ.
(iv) Another frequently encountered misconception included the beliefs that, with the exception of the blood-brain barrier (BBB), restricted penetration into tissues is physiologically impossible and that diffusion-driven transport will inevitably lead to fast and complete equilibration of solutes (5, 6, 11) . Besides data supporting an important role of active transporters in various non-CNS tissues (143) , studies of capillary physiology based on the fiber matrix theory, which implies the existence of 5-nm capillary pores (36, 90) , have revealed several findings which could be extrapolated to tissue antibiotic distribution. Histological sections have revealed that closed capillaries are not an exquisite feature of the brain but are also present in other organs, such as skeletal muscle or lungs (90) . Thus, the barrier properties of capillaries represent a continuum. This conclusion is also supported by studies which showed that the capillary permeability of, e.g., sucrose, which has a molecular weight (MW) of 342, varies from 270 ϫ 10 Ϫ6 cm/s in mesenteric capillaries to 6 ϫ 10 Ϫ6 to 9 ϫ 10 Ϫ6 cm/s in muscle capillaries and 0.1 ϫ 10 Ϫ6 cm/s in CNS capillaries (36, 90, 102, 132) . Interestingly, capillary permeabilities for glucose (MW, 180) and oxygen (MW, 32) are approximately 2 and 10,000 to 20,000 times, respectively, higher than that for sucrose in continuous capillaries (90) . Permeability quickly decreases for compounds with higher MWs, e.g., cyanocobalamin (MW, 1,355), for which skeletal muscle capillaries show restricted diffusion (36, 90, 102, 132) . Thus, it is likely that molecules such as vancomycin (MW, 1,449) follow similar patterns.
Apart from MW, it is seldom considered that for most capillaries, only 0.1% of the capillary surface is available for the transfer of hydrophilic solutes, whereas this value is 100% for lipophilic solutes, e.g., anesthetics (90) . Additional factors, such as Frank-Starling mechanisms (90) and Gibbs-Donnan equilibria (90) with interstitial glycosaminoglycans and paracrine mediators, such as bradykinin, or systemic factors, such as exercise, affect solute transfer from the plasma to the ISF. These mechanisms are well established but are seldom recognized for antibiotics; in addition, due to a lack of methodology, only scant data are available from experiments designed to study the effect of capillary permeability on the transcapillary transfer of antibiotics. The limited available data, however, indicate that blood-tissue equilibrium is tissue specific and may be incomplete, at least for prolonged periods of time ( Fig. 1  and 3 ).
METHODS FOR STUDIES OF TARGET SITE DRUG DISTRIBUTION IN ANTIMICROBIAL CHEMOTHERAPY
PK studies are an integral and often decisive component of anti-infective drug development and also are needed to provide data on tissue drug distribution. Clinical tissue drug distribution studies are also encouraged by regulatory agencies, such as the Food and Drug Administration (FDA) in the United States and the European Medicines Evaluation Agency (EMEA) in Europe (58, 159) . According to current guidance documents for industry (58, 159) , these agencies require measurements of the distribution of antibiotics to unaffected and infected target sites and require the unbound drug concentration at the site of action to be related to the in vitro susceptibility of the infecting microorganism (159) . For these purposes, several experimental methods have been developed and are discussed below.
Traditional techniques. (i) Indirect methods. For many years, direct assessment of tissue drug concentrations was beyond technical reach. Therefore, several mathematical algorithms were used to obtain indirect information about peripheral compartments from plasma-derived data. These algorithms were based on compartment (20, 43) or physiological (3, 20, 125) concepts. As discussed above, however, indirect modeling of tissue drug levels from plasma drug concentration curves relies on several assumptions that, in most situations, do not hold true.
(ii) Direct methods. Due to the inherent limitations of indirect approaches, several experimental tools were developed to determine antibiotic concentrations in various surrogates for the ISF. These approaches comprised the use of in vitro models, fibrin clots, tissue chambers, skin chambers, wound exudates, surface fluids, implanted fibrin clots, and peripheral lymph. These methods were reviewed by several groups of investigators (5, 6, 10, 11, 12, 130, 144, 183, 185) ; Wise (185) concluded that they "only yield limited information on tissue penetration as they often have no pathophysiologic counterpart in humans."
Given the conceptual problems with these techniques, which were mostly limited to one-point measurements in a few clinical settings, skin blister sampling (SBS) became the most frequently applied approach for obtaining the information requested by regulatory agencies. Therefore, there are many available data on the penetration of various antibiotics into cantharis-or suction-induced skin blister fluid (9, 17, 19, 23, 30, 60, 71, 111, 137, 138, 146 ). These studies were justified by the notion that "skin blister fluid levels are closer to the biophase than blood" (138) . Although closer to the biophase than blood, SBS is only a conceptual extrapolation of plasma-based modeling procedures, resulting in a better-defined "second compartment." Skin blister fluid, however, is hardly representative of ISF in other organs, such as the brain. SBS usually also provides no information on the unbound drug fraction and is prone to artifacts due to differences in blister size, surface area/volume ratio, and diffusion capacity across the blister basis (17) and due to the inflammation which accompanies the induction of skin blisters (30; Williams et al., Clin. Pharmacol. Ther. 69: P61). Furthermore, a direct comparison with newer technologies revealed that SBS has many methodological disadvantages (19, 23, 30, 60) .
The large amount of information on the distribution of antibiotics into skin blisters led to incorrect interpretations because many investigators referred to the event of skin blister penetration as "tissue penetration," a wording that has con- FIG. 3 . Tissue drug distribution may be substantially altered by disease state. Mean unbound drug concentration-time profiles were plotted for piperacillin in serum and in the ISF of skeletal muscle tissue of healthy volunteers (left panel) and intensive care patients on a heart-lung machine following heart operations (right panel) after a single intravenous bolus administration of 4 g. The data are presented as means and standard errors. The data are from reference 22. tributed to some of the above misconceptions and should probably be avoided.
Thus, although these techniques were an attempt to overcome the limitations of plasma-based modeling procedures by gaining direct access to tissues, the interpretation of the data was hampered by the inability to discriminate free drug concentrations in ISF. Also, it was typically not possible to record the entire tissue drug concentration-time profile, since most sampling procedures allowed for only one sampling point at a given site.
Novel clinical techniques. (i) Imaging techniques. As a conceptual extension of autoradiography (7, 145, 173) , several novel imaging methods that lend themselves to the study of drug distribution in humans were developed (26, 53, 55, 56, 57, 61, 64, 74, 77, 83, 88, 128, 147, 150, 156, 158, 182, 187) . These comprised radiopharmaceutical techniques, such as two-dimensional planar gamma scintigraphy (PGS) (88, 174) , and three-dimensional techniques, such as single photon emission computed tomography (SPECT) (26, 61, 77, 182) , positron emission tomography (PET) (56, 57, 128, 188) (Fig. 1) , and magnetic resonance spectroscopy (MRS) (83, 129, 187) , which does not require radioactive labeling. Although these techniques mainly were introduced to clinical medicine for various diagnostic purposes (150) and for the study of tissue metabolism and blood flow (128) , they also opened a unique opportunity for PK research. They enabled for the first time noninvasive measurement of the path of a drug from the plasma compartment to anatomically defined regions ( Fig. 1 ) and visualization of the entire pattern of distribution in given organs.
(a) Two-dimensional techniques. PGS was the first available technique and has been used frequently for various PK studies. Typically the test formulation is labeled with the gamma-emitting nucleotide 99m Tc, and the label density is studied over defined regions of interest. The greatest disadvantage of PGS is that it can generate only two-dimensional pictures and therefore does not allow different overlying tissues to be distinguished. PGS has been used extensively to study the patterns of disposition of aerosols in the lungs, including studies on antibiotics such as 99m Tc-labeled tobramycin (88, 174) . (b) Three-dimensional techniques. The shortcomings of PGS were overcome by the introduction of SPECT, which allowed for three-dimensional imaging. The primary focus of SPECT was not the field of anti-infective drug evaluation but cancer research, and it is also used for staging, for diagnostic purposes (such as fever of unknown origin or otitis externa), and for local blood flow measurements (26, 182) . In vivo SPECT studies enabled quantitative measurements of the tissue PK of 57 Co-or 111 In-labeled bleomycin and 195m Pt-cisplatin in humans (61, 77) and indicated that there is marked variability in drug delivery to given tissues. In the field of antibiotic evaluation, SPECT was used to evaluate the penetration of 99m Tc-labeled ciprofloxacin into inflammatory lesions (156) . Although there are only a few reported studies of SPECT in antibiotic PK research, the general applicability seems obvious, as it is already possible to use quantitative SPECT to predict drug responses and to tailor individual chemotherapy in oncology (61, 77) .
Historically, the first technique that enabled three-dimensional radiopharmacokinetic studies was PET, and its application for studies of anti-infective agents has been gleaned from related fields, notably, neuropharmacology (56) . Typically, PET studies are based on compound labeling with 11 C, 13 N, 13 O, or 18 F (56). Several published studies have shown the general applicability of PET in the field of antibiotic evaluation, albeit it involves the burden of high costs (55, 56, 57, 188) . Erythromycin was the first antibiotic studied by PET, in 1982 (188) . In that study, the time course of 11 C-labeled erythromycin accumulation in inflamed lung tissue of patients with pneumonia was described (188) . Unfortunately, radiolabeling of antibiotics is not a simple undertaking, and most antibiotics do not lend themselves to appropriate labeling conditions (56) . Another compound that was studied is fluconazole, because it is an ideal candidate for 18 F labeling and undergoes only minimal metabolism in vivo (56), a property which implies that the signal is representative of the intact drug concentration. A class of compounds that follows similar patterns for PET studies are the fluorinated quinolones, and studies were performed with trovafloxacin (57) (Fig. 1) , lomefloxacin (158) , and fleroxacin (83) . Although these measurements would be useful for many other drugs, the requirement of devising new synthetic procedures is a major limitation.
Like the application of PET and SPECT, the application of MRS for studies of anti-infective agents has been gleaned from anticancer drug research. However, it is surprising that there are only a few studies on antibiotics in the literature. As shown by Jynge et al. (83) , magnetic resonance imaging has proven to be particularly feasible for fluorinated antibiotics, since 19 F is one of the lead isotopes for nuclear magnetic resonance spectroscopy. It was shown that fleroxacin could be detected in 19 F magnetic resonance spectra from both liver and calf muscle at 6-h imaging intervals during a 24-h period (83) . That study documented for the first time the potential use of 19 F MRS to observe noninvasively the time-related changes for a fluorinecontaining drug.
Altogether, the imaging techniques provided for the first time a means to quantify the between-or within-subject variability associated with the distribution process in vivo in humans. In particular, they provided evidence that distribution contributes more to total variability in the dose-effect relationship than the combination of factors determining the plasma drug concentration profile (48, 56, 113) . PET and MRS were also shown to support the definition of optimal dosing schedules in phase I and II studies and the design of phase III studies (56) . Important limitations of these techniques are that (i) only drugs that lend themselves to radiolabeling or the induction of an appropriate magnetic response may be studied; (ii) the signal is not necessarily a measure of the intact drug concentration; and (iii) these techniques do not provide information about specific tissue compartments, such as the ISF. Agencies such as the FDA are therefore very cautious in using results from imaging studies for regulatory purposes (106) . At present, the use of these techniques is also limited to large research centers with good funding opportunities.
(ii) MD. One of the most promising tools for the measurement of tissue drug distribution is in vivo microdialysis (MD) (52, 54, 115, 172) . MD was initially designed to measure concentrations of various neurotransmitters in the rat brain and was gradually adopted for other research areas, including preclinical PK (52) . The increasing use of MD for human PK studies as well (68, 100, 115, 141) was catalyzed by the avail-VOL. 48, 2004 MINIREVIEW 1445 ability of commercially available MD probes and by the refinement of chemical analytical procedures (96, 97) , which today, at least theoretically, allow for online measurements of concentrations in the ISF. In contrast to the imaging techniques, MD can be used readily and routinely for clinical and preclinical studies in almost any research center. The principles of MD have been decribed in detail elsewhere (52, 54, 115, 172) . Briefly, MD is based on the diffusion of drugs across a semipermeable membrane at the tip of an MD probe implanted into the ISF of the tissue of interest. The probe is constantly perfused with a physiological solution (perfusate) at a low flow rate, 1 to 10 l/min. Once the probe is implanted into the tissue, substances present in the ISF are filtered by diffusion out of the extracellular fluid into the probe, resulting in their presence in the perfusion medium (dialysate). Samples are collected and analyzed. To obtain concentrations in the ISF from concentrations in the dialysate, MD probes need to be calibrated. Although several techniques can be used for that purpose, the most suitable technique for human PK studies is an approach proposed by Ståhle et al. (151) , the retrodialysis or delivery method. The principle of this method relies on the fact that the diffusion process is quantitatively equal in both directions through the semipermeable membrane. Therefore, the study drugs are added to the perfusion medium and the rate of disappearance through the membrane equals in vivo recovery. The in vivo percent recovery is calculated as follows: 100 Ϫ [(100 ϫ (analyte concentration in the dialysate/analyte concentration in the perfusate)]. When proper in vivo calibration procedures were used, intraindividual variation coefficients for drug concentration measurements obtained by MD were shown to range between 10 and 20% for different analytes (2, 107, 149, 192) .
Whereas the new cost-and labor-intensive imaging techniques are not readily applicable in clinical routine settings for PK studies and are available only for a small number of compounds, in vivo MD offers the opportunity to study the distributions of a large variety of chemical entities in many different clinical settings. Under appropriate ethical conditions, in vivo MD is feasible for virtually every human tissue. The particular advantage of MD in studies of anti-infective agents, however, relates to the fact that MD allows for the online measurement of the unbound, i.e., pharmacologically active, drug fraction in the ISF, i.e., the space which directly surrounds the target structures. Conceptually, MD thus represents the sole scientific tool currently available with the ability to satisfy the abovestated regulatory requirements (58, 159) , and its use as a tool in clinical PK studies of anti-infective agents has been discussed by FDA advisory committees (59) .
(a) Animal studies with MD. To date, MD has been used to measure in animals the tissue PK of various antimicrobial agents, including quinolones (123, 171) , such as pefloxacin (171) ; chloramphenicol (160, 161, 168) ; ␤-lactams, such as cephalosporins, notably, cefazolin (165) , cephalexin (166) , cefotaxime (167), cefmetazole (162) , cefuroxime (164), cephalothin (28) , ceftriaxone (66, 85, 124, 163) , ceftazidime (66, 169, 178) , cephaloridine (170) , cefamandole (194) , cefoperazone (29) , and cefaclor (40); penicillins, notably, penicillin G (27), piperacillin and tazobactam (37, 118) , amoxicillin (148) (91), and stavudine (193) , and of the antifungal agent fluconazole (191, 192) .
In the field of neuropharmacology, MD is frequently used as a screening tool for neurological drug development because it enables the selection of drug candidates which can cross the BBB (D. Welty, Abstr. 2nd Int. Symp. Microdialysis Drug Res. Dev., abstr. 6, 2000). In addition, MD offers the opportunity to quantify the brain penetration properties of various drugs. For anti-infective agents, several studies found significant differences in levels in blood versus brain, e.g., for cephalosporins (162, 163, 164, 165, 166) and rifampin (103), with penetration ratios ranging from 0.3% for rifampin to approximately 4% for cefuroxime. In contrast, significant distribution in the brain was shown for fluconazole, with a dose-independent brain/tissue ratio of 0.6 (191) . Another study evaluated the ability of ceftriaxone to cross the BBB and analyzed the effects of dexamethasone on the permeative properties of ceftriaxone through quantification of ceftriaxone in dexamethasone-treated animals with meningitis (124) .
Given the important clinical aspects of the distribution of antiviral agents in the brain, e.g., in AIDS patients, several studies addressed the abilities of various antiviral agents to cross the BBB and to attain pharmacologically active concentrations in the brain ISF. For zidovudine, the brain/plasma ratio was 0.09, whereas the liquor/plasma ratio was 0.18 (189, 190) . From these data, it was calculated that the efflux from brain to blood was approximately fivefold higher than the influx from blood to brain. Probenecid was able to decrease the clearance of zidovudine from the brain ISF, thereby prolonging the elimination half-life in brain and increasing the area under the curve (AUC) for the brain by five to sixfold, whereas the AUC for plasma was increased by twofold. These data provide evidence that zidovudine is actively transported out of the brain and that target site exposure could be substantially increased by the coadministration of probenecid. Restricted diffusion across the BBB was also described and quantified for several other antiviral agents (18, 91, 153, 155) . Fluconazole was shown to rapidly reach a distribution equilibrium between brain extracellular fluid and plasma, and the distribution to the brain was shown to be substantial and not dependent on the dose over a twofold range (192) .
Similar to the problem of BBB penetration, it was shown for the eye (176) that the penetration of ceftazidime into the vitreous after intramuscular injection was ϳ50% higher in inflamed than in noninflamed eyes, suggesting interference with the blood-retina barrier (177) . The problem of transport across the blood-retina barrier is particularly important for the treatment of cytomegalovirus retinitis. It was shown that MD could also be used to administer ganciclovir to the rabbit vitreous within the therapeutic range, offering a route of drug delivery that is not possible with conventional ganciclovir implants (178) .
The issue of lung penetration was addressed for several antibiotics, e.g., cefaclor (40) , cefminox, the ␤-lactam SY5555, and faropenem (38) . It was shown that unbound concentrations in ISF in the lungs, muscle, and liver for these compounds were close to the unbound concentrations in plasma. Total tissue drug concentrations also differed widely among the tissues studied (38) . Another group applied MD for intrabronchial measurements of tobramycin and gentamicin (49) . The mean values for penetration ratios into the epithelial lining fluid were 0.36 for gentamicin and 0.56 for tobramycin. The results demonstrated that MD lends itself to intrabronchial and intrapulmonary measurements either as an extension of other techniques, such as bronchoalveolar lavage, or as a practical alternative to other techniques.
For soft tissues, it was shown that total concentrations in plasma were much higher than concentrations in ISF for ceftriaxone (Fig. 4) . After determination of nonlinear protein binding by MD and inclusion of those parameters in the PK model, however, it was possible to predict free drug concentrations in the interstitial space from concentrations in plasma for any given dose. Follow-up studies on the PK of piperacillin and tazobactam (37, 118) , alone and in combination, showed that piperacillin PK were not influenced by the coadministration of tazobactam. Again, it was possible to calculate concentrations in ISF for both drugs based on the protein-bound fraction, and the data showed good agreement with measured ISF concentrations.
MD has been frequently applied to measurements of antibiotics in fluids, such as bile and blood. Although it is generally preferable to sample and analyze these fluids directly, the volume of body fluid that can be obtained from small experimental animals is usually limited. Since MD enables long-term measurements without net fluid loss, it offers a promising alternative to direct sampling for these purposes.
Another interesting and promising approach in this regard is the use of MD for the middle ear fluid of chinchillas-a model which closely resembles the anatomy in the middle ear of human infants. It was shown that for ampicillin, concentrations in the middle ear fluid were only 30% the corresponding concentrations in plasma (Sawchuk et al., Abstr. 2nd Int. Symp. Microdialysis Drug Res. Dev., abstr. 7).
Apart from mere PK measurements, MD may also be used to quantify and monitor biochemical surrogate markers for side effects, e.g., the time course of the changes in perilymphatic glutamate during the application of kanamycin in cases of aminoglycoside-induced ototoxicity (95) .
(b) Human studies with MD. To date, MD has been used to measure in humans the tissue PK of various antimicrobial agents, including gentamicin (93, 107) , ciprofloxacin (24) , moxifloxacin (114) , fleroxacin (107) , cefodizime (107, 110) , cefpirome (107, 110) , piperacillin (22) , dirithromycin (107), cefaclor (41) , and fosfomycin (62), and antiviral agents, such as penciclovir (19) , in the soft tissues of healthy volunteers.
Following the first publication on the use of MD for clinical antibiotic studies in 1995 (107) , MD has been used to address various questions in anti-infective agent research, such as the influence of protein binding (110) , of PK surrogate markers in tissues, and of different administration schedules and galenic formulations (73) on antibiotic distributions in various tissues. In addition, it was shown, in principle, that the concept of markers of PK and pharmacodynamics (PD), e.g., the time above the MIC (TϾMIC), the AUC/MIC ratio, the ratio of the maximum concentration of drug in serum (C max ) to the MIC, or the area under the inhibitory curve, for the evaluation of antibiotic regimens, originally developed for serum PK, can be extended to peripheral tissue PK by means of MD (41, 107, 114) .
MD studies showed that the concentrations in ISF of selected antibiotics, e.g., fleroxacin (107) , ciprofloxacin (24) , or dirithromycin (107), correspond to unbound concentrations in plasma and are much lower than concentrations reported from whole-tissue biopsy specimens. For cefpirome, it was shown that in soft tissue infections with selected bacteria, continuous infusion may substantially prolong the TϾMIC at the target site (73) . Similarly, a comparative study on an immediate-or a modified-release formulation of cefaclor revealed that the TϾMIC at the target site can be substantially prolonged when an antibiotic is administered as a sustained-release product (73) .
Altogether, these studies with healthy volunteers led to a reappraisal of formerly believed concepts about the tissue penetration of antimicrobial drugs. Concentrations of ␤-lactams and aminoglycosides in ISF are mostly in the range of free concentrations in serum (110) (Fig. 3) , whereas for quinolones and macrolides, target site concentrations are considerably lower than those predicted from tissue biopsy specimens (107) . The results of these MD studies further demonstrated that concentrations of antimicrobial agents at target sites may be subinhibitory even though effective concentrations are attained in serum (24) .
In patients, MD was used to quantify the effects of obesity (22), intensive care procedures (22, 80) , and septicemia (80) on peripheral drug distribution; to study the effects of inflammation on antibiotic penetration into foot lesions in patients with diabetes (89, 112) and dermatological conditions (107) ; and to measure antibiotic penetration into the lungs (70) and the brain (25, 105) . In a study on the distribution of phenoxymethylpenicillin in patients with cellulitis (107) , no difference could be detected in the time courses of phenoxymethylpenicillin in inflamed dermis versus noninflamed dermis. Similarly, there was no significant difference in the penetration of ciprofloxacin (112) or fosfomycin (89) into unaffected tissue and acutely inflamed foot lesions. In contrast, significantly reduced target site penetration was observed for ciprofloxacin in patients with arterial occlusive disease (82) and for fosfomycin in patients with longterm diabetes mellitus (89) , probably due to impaired capillary density. Thus, it appears that local blood flow and alterations in the capillary surface area are important determinants of concentrations in ISF, whereas acute inflammatory events seem to have little influence on tissue penetration. These observations are in clear contrast to reports on the increase in the target site availability of antibiotics by macrophage drug uptake and the preferential release of antibiotics at the target site (140), a concept which is also used as a marketing strategy by the drug industry.
Recently, Hollenstein et al. (72) addressed the issue of tissue penetration of ciprofloxacin in obese subjects with a mean weight of 122 kg and age-and sex-matched lean control subjects and found ϳ50% lower tissue AUC/plasma AUC ratios in obese subjects. Thus, the process of penetration into the ISF is markedly impaired in obese subjects, most likely because of a reduced capillary permeability surface area in fat tissue (72) .
Apart from studies in easily accessible soft tissues, MD has been adopted for measurements in other organs, including the lungs and the brain. The application of clinical lung MD was shown in a study of cefpirome (70) penetration into lung ISF in patients undergoing lung surgery due to malignancies. Such pilot studies, which have opened the opportunity for future studies on antibiotic penetration in the lungs, have provided evidence for the feasibility of lung MD and have shown that drug distribution in the unaffected lung is driven by unrestricted diffusion. Mindermann et al. published the first report on the study of antibiotic PK in the human brain by MD in 1998 (105) . They determined the in vivo penetration of rifampin into various compartments of the human brain in patients undergoing craniotomy for resection of primary brain tumors. Rifampin concentrations in all compartments exceeded the MICs for staphylococci and streptococci. However, concentrations in ISF might have been below the MICs for some mycobacterial strains. In another recent study, the intracerebral penetration of fosfomycin was studied by MD in intensive care patients with intracerebral hemorrhage requiring neurosurgical intensive care, including cerebrospinal fluid drainage (25) . Intracerebral C max s of fosfomycin were above the MICs for clinically relevant bacteria causing CNS infections and ranged between 13 and 79 g/ml. Fosfomycin therefore might qualify as a therapeutic option in the treatment of CNS infections, such as meningitis, meningoencephalitis, or brain abscesses.
A significant problem with antibiotic penetration was shown for compromised patients (22, 80, 157) . In particular cardiac surgery and intensive care procedures significantly lowered tissue AUC/serum AUC ratios in the patients, and inadequate target site concentrations were frequently attained (22) (Fig.  4) . In a follow-up study on patients with septic shock, these findings were even more pronounced, as piperacillin concentrations in soft tissue ISF were up to 10-fold lower than corresponding free concentrations in plasma (80) . Piperacillin concentrations in subcutaneous adipose tissue in patients with septic shock did not exceed values below the MICs for a large range of relevant pathogens. It thus appears that capillary damage associated with septicemia or postoperative trauma significantly affects drug concentrations. This finding may have clinical implications in that current dosing guidelines might result in inadequate target site concentrations and could lead to therapeutic failure in some patients.
INTEGRATION OF DISTRIBUTION STUDIES IN PK-PD STUDIES OF ANTI-INFECTIVE AGENTS
The traditional approach to linking antibiotic concentrations to antibiotic effects is to relate a static parameter, the MIC, to the concentration in serum. This approach is usually applied by using cumulative PK-PD variables, such as AUC/MIC ratios, TϾMIC, or C max /MIC ratios (20, 44) . However, these approaches do not take into account the complex interactions among an administered drug, a host, and an infective agent, since in practice, a PD effect in vivo is the result of a dynamic exposure of the infective agent to the unbound drug fraction at the relevant target site rather than a static interaction of two variables. Therefore, several authors proposed that PK be linked to PD in a more dynamic way by using several PK-PD models (35, 39, 42, 44, 119) .
All of the above techniques not only may provide information on PK but also may lend themselves to studies of antibiotic PD. This is particularly true for MD, as it monitors free antibiotic concentrations in the fluid which directly surrounds the infective agent; the antimicrobial effect linked to the time-drug concentration profile obtained by MD may be simulated easily in an in vitro setting with bacterial cultures. This dynamic simulation may thus provide a rational approach to describing and predicting PD at a relevant target site. Some recent publications described an MD-based in vivo PK-in vitro PD model (39) that is based on a previously described modified maximum effect (E max ) model (42, 119) and that may be used to predict drug effects at the target site.
This three-step approach is based on (i) the in vivo measurement of ISF drug PK at the target site and (ii) the subsequent PD simulation of the time-drug concentration profile in an in vitro setting. In a third step, the data are analyzed with an integrated PK-PD model to link unbound antibiotic concentrations to bacterial killing rates by using E max . Such experiments enable the simulation of different dosing scenarios without the need for large clinical trials (24, 39, 41, 42, 73, 119) . These data could provide strong support for PK-PD modeling procedures, might assist in dose optimization, and might replace current concepts for establishing dosing guidelines for selected tissue infections. This approach is also in accordance with the current reasoning of regulatory authorities, such as the FDA and the EMEA, which not only require measure-ments of the distribution of antibiotics to unaffected and infected target sites but also require the unbound drug concentration at the site of action to be related to the in vitro susceptibility of the infecting microorganism (58, 159) .
CONCLUSIONS AND OUTLOOK
For many years, PK research was limited to blood and plasma drug concentrations measurements. Although it was always acknowledged that the target sites for most drugs are peripheral tissues, concentrations in blood were measured to serve as a basis for therapeutic decisions because they were easy to obtain. Total tissue drug concentrations based on homogenized tissue biopsy specimens further confused the situation. These data, which have commonly been measured in PK studies, are misleading, as they represent hybrid concentrations of free drug and bound drug in different tissue compartments and cannot easily be interpreted correctly.
In recent years, the introduction of novel techniques has provided previously inaccessible information about the process of target site distribution. With the examples presented here, we have tried to illustrate the explosion of new research in the application of these techniques to the measurement of antibiotics in peripheral tissues. MD measurements, in particular, provide a rational and scientifically sound means to directly measure concentrations of unbound anti-infective agents at the site of action.
Given the recent technical advances in the study of tissue drug distribution and the reconsideration of traditional pharmacological paradigms, it is expected that the issue of tissue drug distribution will gain more attention in the future.
